Fujian Akeylink Biotechnology Co., Ltd.
Clinical trials sponsored by Fujian Akeylink Biotechnology Co., Ltd., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug combo aims to silence hepatitis b virus Results expected Oct 2026 (estimated)
- New pill could help hepatitis b patients who Don't respond to standard care Results expected Dec 2026 (estimated)
-
New drug combo aims to silence hepatitis b virus
Disease control Recruiting nowThis phase II trial tests whether two experimental drugs, GST-HG131 and GST-HG141, can safely reduce hepatitis B surface antigen (HBsAg) levels in people with chronic hepatitis B. The study involves 80 adults aged 35-65. Participants receive either the drug combination or a place…
Phase 2 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill could help hepatitis b patients who Don't respond to standard care
Disease control Recruiting nowThis Phase 3 trial tests whether adding GST-HG141 (Neracorvir) to standard antiviral therapy can better suppress the hepatitis B virus in patients who haven't responded adequately to current drugs. About 526 adults with chronic hepatitis B will receive either the experimental dru…
Phase 3 • Sponsor: Fujian Akeylink Biotechnology Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC